Although the results of the present study suggest a shift towards increased risk for breast cancer for the initial year of insulin glargine vs human insulin use, no differences were found for longer durations of treatment, when using appropriate comparators and adjusting for the overall time on insulin. Here, INS is linked to breast cancer.